Portal de Periódicos da CAPES

Antiphosphatidylserine/Prothrombin Antibodies (aPS/PT) as Potential Markers of Antiphospholipid Syndrome

2012; SAGE Publishing; Volume: 19; Issue: 3 Linguagem: Inglês

10.1177/1076029612437578

1938-2723

Alexandru Vlagea, Antonio Gil‐Moreno, María V. Cuesta, F. Arribas, Jesús Díez‐Manglano, Paz Lavilla, Dora Pascual‐Salcedo,

Platelet Disorders and Treatments

The antiphospholipid antibodies present in antiphospholipid syndrome (APS) are directed at a number of phospholipid-binding proteins: β 2 glycoprotein I (β 2 GPI), prothrombin, and so on. Antibodies directed at β 2 GPI are accepted as a classification criterion for APS, while the presence of antiprothrombin antibodies is not. In the present article, we investigated the possible role of antiphosphatidylserine/prothrombin antibodies (aPS/PT) as marker of APS on a cohort of 295 individuals with APS (95 primary APS and 45 secondary APS) and APS-related diseases. We found aPS/PT to be highly associated with venous thrombosis (immunoglobulin G [IgG] aPS/PT odds ratio [OR], 7.44; 95% confidence interval [CI], 3.97-13.92 and IgM aPS/PT OR, 2.54; 95% CI, 1.35-4.77) and obstetric abnormalities (IgG aPS/PT OR, 2.37; 95% CI, 1.04-5.43), but not with arterial thrombosis. A very high degree of concordance between the concentration of aPS/PT and lupus anticoagulant activity was demonstrated. Therefore, we support the inclusion of aPS/PT determination as second-level assay to confirm APS classification.